Health
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society f
About this update from Theriva Biologics, Inc.
[{"type":"image","alt":"Theriva Biologics, Inc.","displaySize":"","headline":null,"caption":"Theriva Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NwCW1pyw7ahIW1qecrDFNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a","width":300,"height":102}},"lazy":false},{"type":"text","content":"- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 -","length":86,"tagName":"p"},{"type":"text","content":"- SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 -","length":90,"tagName":"p"},{"type":"text","content":"Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society for Medical Oncology (ESMO 2025) Annual Congress and at Infectious Diseases Week (IDWeek) 2025 Annual Meeting.","length":431,"tagName":"p"},{"type":"text","content":"VCN-01 upcoming mini-oral presentation at ESMO 2025Expanded data from the VIRAGE trial investigating VCN-01 (zabilugene almadenorepvec) are to be presented at a mini oral session at the ESMO 2025 Congress:","length":206,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presenting author: Dr. Rocío Garcia-Carbonero, Hospital 12 de Octubre, Madrid, Spain","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Title: VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract #: 2216MO","length":18,"tagName":"p"}]},{"val":[{"type":"text","content":"Date and time: Monday, October 20, 2025, 09:28 a.m. CEST","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Mini oral session 2, GI Tumors Upper digestive","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Bonn Auditorium - Hall 7.1c, Messe Be...